Want to see RMTG full AI Analyst Report?
RMTG Stock Chart & Stats
$0.02
>-$0.01(-26.32%)
At close: 4:00 PM EST
$0.02
>-$0.01(-26.32%)
Day’s Range― - ―
52-Week Range$0.02 - $0.12
Previous CloseN/A
Volume89.42K
Average Volume (3M)8.37K
Market Cap
$696.37K
Enterprise Value$20.06M
Total Cash (Recent Filing)$1.06M
Total Debt (Recent Filing)$20.58M
Price to Earnings (P/E)―
Beta-1.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,138,968
10 Day Avg. Volume641
30 Day Avg. Volume8,365
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.12
P/FCF Ratio-0.47
Enterprise Value/Market Cap28.81
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda17.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue is scaling rapidly (high mid-teens to high-30s percent growth in recent periods), showing durable top-line traction. For a small biotech, sustained revenue growth expands addressable-market penetration, supports future operating leverage, and underpins longer-term investment in R&D and commercialization.
Healthy Gross Margin & EBITDAA roughly 57% gross margin and a move to slightly positive TTM EBITDA indicate the business model can generate strong unit economics. If revenue scale continues, these margins support sustainable operating leverage, making it easier to absorb fixed costs and drive towards consistent operating profitability.
Cash Burn Below GAAP Loss (non-cash Charges)Operating and free cash flow are less negative than GAAP losses, implying significant non-cash charges. This reduces immediate cash strain relative to reported net losses, lengthening runway and lowering near-term refinancing pressure — an important structural buffer for development-stage biotech firms.
Bears Say
Negative EquityPersistent negative equity reflects accumulated losses and undermines financial flexibility. Over time this limits access to traditional borrowing, increases reliance on dilutive equity or expensive financing, and signals that capitalization must be repaired before the company can sustainably scale without repeated external funding.
High Leverage Vs. Small Asset BaseDebt materially exceeds the asset base, creating refinancing and covenant risk. For a small-company balance sheet, high leverage increases probability of financing distress or restrictive terms on future capital, which can constrain R&D, commercialization, and strategic flexibility over the next several months to years.
Negative Operating & Free Cash FlowOperating and free cash flow remain negative, implying ongoing external funding needs absent rapid margin improvements. Continued negative FCF forces management to seek capital, risking dilution or high-cost debt, and may pressure investment pacing in development programs and commercial initiatives over the medium term.
Regenerative Medical Technology Group News
RMTG FAQ
What was Regenerative Medical Technology Group’s price range in the past 12 months?
Regenerative Medical Technology Group lowest stock price was $0.02 and its highest was $0.12 in the past 12 months.
What is Regenerative Medical Technology Group’s market cap?
Regenerative Medical Technology Group’s market cap is $696.37K.
When is Regenerative Medical Technology Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regenerative Medical Technology Group’s earnings last quarter?
Currently, no data Available
Is Regenerative Medical Technology Group overvalued?
According to Wall Street analysts Regenerative Medical Technology Group’s price is currently Overvalued.
Does Regenerative Medical Technology Group pay dividends?
Regenerative Medical Technology Group does not currently pay dividends.
What is Regenerative Medical Technology Group’s EPS estimate?
Regenerative Medical Technology Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regenerative Medical Technology Group have?
Regenerative Medical Technology Group has 13,138,968 shares outstanding.
What happened to Regenerative Medical Technology Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regenerative Medical Technology Group?
Currently, no hedge funds are holding shares in RMTG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Regenerative Medical Technology Group
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
Technical Analysis
Bone Biologics
―
INVO Fertility
―
Bluejay Diagnostics
―
NewGenIvf Group
―
WORK Medical Technology Group LTD
―